PREPS and L-particles: a new approach to virus-like particle vaccines

References

• Boisgerault F et al. Virus-like particles: a new family of delivery systems. Expert Rev Vaccines 1(1) 101–109 (2002).
   PubMedGoogle Scholar
• Breitburd F et al. Human papillomavirus vaccines. Cancer Biology9, 431–445 (1999).
   Google Scholar
• Evans TG et al Phase 1 study of a recombinant VLP vaccine against HPV 11 in healthy adult volunteers. j Infect. Dis.183, 1485–1493 (2001).
   Google Scholar
• Sedlik C et al. Recombinant parvovirus-like particles as an antigen carrier: a novel Nonreplicative exogenous antigen to elicit protective antiviral cytotoxic T-cells. Proc. Nat! Acad. Sc]. USA 94 (14), 7503–7508 (1997).
   Google Scholar
• Greenstone HL et al Chimeric papillomavirus virus like particles elicit antitumour immunity against the E7 oncoprotein in an HPV16 tumor model. Pmc. Natl Acad. Sc]. USA 95 (4),1800— 1805 (1998).
   Google Scholar
• Roizman B, Seam A. Herpes simplex viruses and their replication. In: Vimlog); 21(1 Frlition.Fields BN, Knipe DM, Howley PM etal. (Eds), Lippincott-Raven, Philadelphia, PA, USA (1996).
   Google Scholar
• Szilagyi JF, Cunningham C. Identification and Characterization of a novel non- infectious herpes simplex virus related particle.j Gen. Viral. 72, 661–668 (1991).
   Google Scholar
• Stevens AC, Spear, PG. Herpesvirus capsid assembly and envelopment. In: Structural Biology of Viruses. Chui W, Burnett RIVI, Garcea RL (Eds). Oxford University Press, UK, 312–351 (1997).
   Google Scholar
• McLaughlan J, Rixon E Characterization of enveloped tegument structures(L Particles) produced by alpha herpes viruses: integrity of the tegument does not depend on the presence of capsid or envelope. j Gen. Virol. 73, 269–276 (1992).
   Google Scholar
• Dargan DJ, Patel A, Subak-Sharpe JH. PREPS: Herpes simplex virusType 1 specific particles produced by infected cells when viral DNA replication is blocked. Virol. 69, 4924–4932 (1995).
   Google Scholar
• Rixon FJ, Addison C, McLauchlan J. Assembly of enveloped tegument structures ( L particles) can occur independently of virion maturation in herpes simplex virus Type 1-infected cells. j Gen. Viral 73, 277–284 (1992).
   Google Scholar
• McLauchlan J, Addison C, Craigie M, Rixon E Non-infectious L particles supply functions which can facilitate infection by HSV-1. Virology 190,682–688(1992).
   Google Scholar
• Dargan DJ, Subak-Sharpe JH. The effect of herpes simplex virus Type 1 L-particles on virus entry, replication and the infectivity of naked herpesvirus DNA. Virology 239, 378–388 (1997).
   Google Scholar
• Zhang Y, McKnight JLC. Herpes simplex virus Type 1 UL46 and UL47 deletion mutants lack VP11 and VP12 or VP13 and VP14 respectively and exhibit altered viral thymidine kinase expression j Viral 67, 1482–1492 (1993).
   Google Scholar
• Subak-Sharpe JH, Dargan DJ. HSV molecular biology; general aspects of herpes simplex virus molecular biology. jVirus Genes 16 (3), 239–251 (1998).
   Google Scholar
• Fruh K, Ahn K, Djaballah H et al. A viral inhibitor of peptide transporters for antigen presentation. Nature 375,415–418 (1995).
   PubMed Web of Science ®Google Scholar
• Boursnell ME, Entsile C, Blakeley D et al. A genetically inativated herpes simplex virus Type 2 (HSV2) vaccine provides effective protection against primary and recurrent HSV-2 disease.' Infect. Dis. 170, 1100–1109 (1994).
   Google Scholar
• Andrew ME. Protective efficacy of a recombinant vaccinia virus in vaccinia-immune mice. Iminunol Cell Biol. 67, 339–341(1989).
   Google Scholar
• Papp Z, Babiuk LA, Baca-Estrada ME. The effect of pre-existing adenovirus-specific immunity on immune responses induced by recombinant adenovirus expressing glycoproteinD of bovine herpes Type 1. Vaccine 17,933–943 (1999).
   Google Scholar
• Schlesinger S. Alphavirus vectors: development and potential therapeutic applications. Expert Opin. Biol. Ther.1 (2), 177–191 (2001).
   Google Scholar
• Mandl S et al Preexisting immunity to poliovirus does not impair the efficacy of recombinant poliovirus vaccine vectors. Viral 75(2), 622–627 (2001).
   Google Scholar
• Belyakov IM, Moss B, Strober W Berzofsky JA. Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity. Proc. Natl Acad. Sri. USA 96,4512–4517 (1999).
   Google Scholar
• Irvine KR et al Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors. Natl Cancer Inst. 89(21), 1595–1601 (1997).
   Google Scholar
• Kundig TM, Kalberer CP, Hengartner H, Zinkernagel RM. Vaccination with two different vaccinia recombinant viruses: long-term inhibition of secondary vaccination. Vacci7e11,1154–1158 (1993).
   Google Scholar
• Lambright ES et al Effect of preexisting antiherpes immunity on the efficacy of herpes simplex viral therapy in a murineip. tumor model. Mol. Ther 2 (4), 387–393 (2000).
   Google Scholar
• Chahlavi A et al. Effect of prior exposure to herpes simplex virus 1 on viral vector-mediated tumor therapy in immunocompetent mice. Gene Ther. 6(10), 1751–1758 (1999).
   Google Scholar
• Delman KA et al Effects of preexisting immunity on the response to herpes simplex-based oncolytic viral therapy. Hum. Gene Ther. 11(18), 2465–2472 (2000).
   Google Scholar
• Brockman MA et al Herpes simplex virus vectors elicit durable immune responses in the presence of preexisting host immunity. Viral 76 (8), 3678–3687 (2002).
   Google Scholar
• Lenz P, Day PM, Pang YY et a/. Papillomavirus-like particles with immune cells. hit. Immund 13(5), 633–641 (2001).
   Google Scholar